EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges

Takashi Matsuoka, Shusuke Akamatsu, Christopher J Ong iD, Martin E Gleave, Yuzhuo Wang iD

Cells · 26.03.2026 · 15 (7) · 588

DOI: 10.3390/cells15070588 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.03.2026. Verfasst von Takashi Matsuoka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Pacific Northwest Prostate Cancer SPORE, BCCF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(ADP-ribose) polymerase inhibitors (PARPi) have reshaped therapy for advanced prostate cancer, yet durable benefit remains concentrated in BRCA1/2-altered tumors, especially BRCA2, and most responders eventually relapse. Here, we frame PARPi response and resistance through a unifying model in which DNA damage response (DDR) rewiring (e.g., homologous recombination repair (HRR) restoration, fork protection, checkpoint tolerance, and altered drug handling) converges with treatment-induced dormancy and quiescent therapy-tolerant residual states that sustain minimal residual disease (MRD) under androgen receptor pathway inhibition (ARPI) and PARP blockade. We synthesize clinical and translational evidence for PARPi monotherapy and PARPi-based combinations across disease states. In first-line metastatic castration-resistant prostate cancer (mCRPC), PARPi plus ARPI consistently prolongs radiographic progression-free survival, with the greatest benefit in HRR-altered tumors, and emerging overall-survival signals in selected subgroups. In later-line settings, monotherapy activity is most robust in BRCA2-mutated disease, whereas non-BRCA HRR alterations show heterogeneous and often modest responses, underscoring the need for biomarkers beyond gene panels. We also discuss combination strategies with DDR-targeting agents, radioligand therapies, and immunotherapy, and summarize ongoing phase III programs in metastatic castration-sensitive prostate cancer (mCSPC). Finally, we outline practical considerations for biomarker-informed patient selection, monitoring, sequencing, and toxicity management, with particular emphasis on intercepting MRD and resistance evolution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmProstatic NeoplasmsHumansMaleProstatic Neoplasms, Castration-Resistant

Stichwörter der Autor:innen

BRCA1/2PARP inhibitorsandrogen deprivation therapy (ADT)androgen receptor pathway inhibitors (ARPI)biomarkerscombination therapyhomologous recombination repair (HRR)metastatic castration-resistant prostate cancer (mCRPC)metastatic castration-sensitive prostate cancer (mCSPC)

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada.
  • Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
  • Department of Urologic Sciences, Faculty of Medicine, The University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
  • Department of Urology, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.

ORCID-Profile: Christopher J Ong, Yuzhuo Wang

Förderung

  • NCI NIH HHS
  • Pacific Northwest Prostate Cancer SPORE
  • BCCF
  • Terry Fox Research Institute
  • Terry Fox Research Institute https://ror.org/00mtf6c40
  • BC Cancer Foundation (BCCF) https://ror.org/03gqhbs95

Zitieren

APA

Matsuoka, T., Akamatsu, S., Ong, C. J., Gleave, M. E., & Wang, Y. (2026). PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges. Cells, 15(7), 588. https://doi.org/10.3390/cells15070588

Vancouver

Matsuoka T, Akamatsu S, Ong CJ, Gleave ME, Wang Y. PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges. Cells. 2026;15(7):588. doi:10.3390/cells15070588

BibTeX
@article{Matsuoka2026,
  author = {Matsuoka, Takashi and Akamatsu, Shusuke and Ong, Christopher J and Gleave, Martin E and Wang, Yuzhuo},
  title = {PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {588},
  doi = {10.3390/cells15070588}
}
Kostenlos starten →